Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q1 FY23 Earnings Presentation
16 slides from Zim Laboratories's earnings presentation, July 2022
Slide 1: Zim Laboratories Limited Q1 FY23 Investor Presentation
Z I M L A B O R ATO R I E S L I M I T E D Q1 FY23 INVESTOR PRESENTATION J U LY 2 0 2 2
Slide 2: Contents
CONTENTS BUSINESS OVERVIEW FINANCIAL OVERVIEW CORPORATE INFORMATION 05 BUSINESS HIGHLIGHTS 15 OWNERSHIP 10 TOTAL OPERATING INCOME 06 OUR BUSINESS 11 EBITDA & PROFIT AFTER TAX 07 EXPORTS BUSINESS 12 RESEARCH & DEVELOPMENT 08 DOMESTIC BUSINESS 13 INCOME STATEMENT : CONSOLIDATED
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Business Overview
zm Teal & Innovation in Medicine BUSINESS OVERVIEW
Slide 5: Business Highlights
BUSINESS HIGHLIGHTS Total Operating Income for Q1FY23 was Rs927Mn, up 44.5% YoY Pharmaceutical products in our business mix were at Rs617Mn (67%) and Nutraceutical products were at Rs310Mn (33%) ; both segments continued EBITDA for Q1FY23 was Rs131Mn, up from Rs65Mn in Q1FY22 to show healthy growth
Slide 6: Our Business
OUR BUSINESS Pharmaceuticals Nutraceuticals During Q1FY23, our Pharmaceuticals business was During Q1FY23, our Nutraceutical business – Rs 617Mn – or 67% of the Total Operating Income comprising of Vitamins, Healthcare and Dietary Supplements was Rs310Mn – or 33% of the Total Pharmaceuticals busines
Slide 7: Exports Business
EXPORTS BUSINESS 799 758 733 641 528 Our exports business in Q1FY23 was Rs758Mn, up 43% from Rs528 Mn for Q1FY22 Mix of Exports in Total Operating Income in Q1FY23 was 82% (also Q1FY 22 Q2FY 22 Q3FY 22 Q4FY 22 Q1FY 23 82% in Q1FY22) Key regions for exports during the quarter were MENA,SE Asia, 2701
Slide 8: Domestic Business
DOMESTIC BUSINESS Q1FY2022 (RS. 113 MN) 10 4 9% 4% For Q1FY23, our domestic business was Rs169Mn and comprised 18% of our Total 23 Operating Income 20% 59 The domestic business includes sale to Central/ State Government, agencies owned 53% by the Government and sale through deemed exports (products
Slide 9: Financial Overview
zm Zeal & Innovation in Medicine FINANCIAL OVERVIEW.
Slide 10: Total Operating Income
TOTAL OPERATING INCOME 1050 927 867 775 642 Total Operating Income grew to Rs927Mn in Q1FY23 from Rs642Mn in Q1FY22 Q1FY 22 Q2FY 22 Q3FY 22 Q4FY 22 Q1FY 23 All our lines of business grew in Q1FY23 Vs Q1 FY22 and the mix was same for exports (82%) during this period; there was a small change in mix f
Slide 11: EBITDA & Profit After Tax
EBITDA & PROFIT AFTER TAX EBITDA In Rs. Mn and as % of Total Operating Income 164 114 131 111 Our Net Contribution (Total Operating Income less Variable Costs) 15.6% continued to grow in Q1FY23, mainly on account of the change in mix in 65 14.1% 14.3% the products and better realisations from our ex
Slide 12: Research & Development
RESEARCH & DEVELOPMENT R&D Expense (In Rs. Mn and as % of Total Operating Income) 3 Our R&D expenses for Q1FY23 was 5.5% of our Total Operating 5 Income 3 52 Around 80% of the expenses for Q1FY23 were incurred on salary, materials, BE and other study etc. for the R&D team and the balance 10.8% 8 was
Slide 13: Income Statement: Consolidated
INCOME STATEMENT : CONSOLIDATED Key Financial Highlights: Income Statement (Rs. Mn) Particulars Q1 FY23 Q1 FY22 Change % (YoY) Q1 FY 23 Q4 FY 22 Change % (QoQ) Total Operating Income 927 642 44.4% 927 1050 (11.7)% Other Income 19 12 58.3% 19 17 11.8% Total Income 946 654 44.6% 946 1067 (11.3)% EBITD
Slide 14: Corporate Information
zm Zeal & Innovation in Medicine CORPORATE INFORMATION
Slide 15: Ownership
OWNERSHIP Overall Shareholding % Public Shareholding % 5% 5% Promoter Group shareholding is free of any encumbrance 35% 1Mn equity shares (6.16% of the 67% diluted capital) of the Company 33% are held under an Escrow arrangement and categorized under “Other Public Shareholding”. 22% These shares may
Slide 16: Thank You
2.mn 1 THANK YOU